Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04531709 · ClinicalTrials.gov registry record
Financial Toxicity and Quality of Life in Patients With TGCT
A clinical trial, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- 24
- Enrollment target
NCT04531709 is a clinical trial that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 24 participants.
The verdict
NCT04531709 has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.
Interventions
- OTHER Comprehensive Score for financial toxicity (COST)
- OTHER Functional Assessment of Cancer Therapy: General (FACT-G)
- OTHER EORTC QLQ C-30
- OTHER EORTC QLQ-TC26.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2025-02-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04531709
The ClinicalTrials.gov registry entry for NCT04531709 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Comprehensive Score for financial toxicity (COST) is the first listed.
NCT04531709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04531709 about?
NCT04531709 is a clinical study titled "Financial Toxicity and Quality of Life in Patients With TGCT". This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of...
What is the current status of trial NCT04531709?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2023-03-01. Estimated completion is 2025-02-04.
What interventions are being tested in trial NCT04531709?
The interventions under investigation include: Comprehensive Score for financial toxicity (COST) (OTHER), Functional Assessment of Cancer Therapy: General (FACT-G) (OTHER), EORTC QLQ C-30 (OTHER), EORTC QLQ-TC26. (OTHER).
Who is sponsoring clinical trial NCT04531709?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.